Steven C. Kline

Steven C. Kline


Partner, New York

Steven Kline has extensive experience in all aspects of complex patent litigation in the pharmaceutical and chemical arts and he has represented leaders in these technology fields. Specific technologies that Steve has worked with include antipsychotic drugs, antiviral drugs (including AIDS and hepatitis B), anticancer drugs, glaucoma drugs, hormone therapy, oral contraceptives, osteoporosis drugs, eye vitamins, contact lens cleaning and disinfecting solutions, medical implant devices, fluidized bed reactor polymerization processes, and carpet dyes. He also has particular experience in litigating ANDA cases brought under the Hatch-Waxman Act.
Case Highlight
AstraZeneca Pharms. LP, et al. v. Anchen Pharms, Inc., et al.
Fed. Cir. (2013)

Steve successfully obtained Federal Circuit affirmance for client AstraZeneca in Seroquel XR® patent dispute against generic competitors who were seeking to obtain FDA approval to market and sell generic copies of AstraZeneca’s patented Seroquel XR® product in the United States.
Representative Matters
  • AstraZeneca against Handa, Anchen, Osmotica, Torrent and Mylan on a patent covering AstraZeneca’s Seroquel XR® formulation and against Teva and Sandoz on a patent covering AstraZeneca’s Seroquel® molecule.
  • Warner Chilcott against Watson, Teva, Ranbaxy, Amneal, and Impax on patents covering Warner Chilcott’s Atelvia® formulation, a formulation for the treatment of osteoporosis.
  • Gilead against Idenix in patent interference proceeding involving novel nucleosides useful for treating HCV.
  • Unigene and Upsher Smith against Apotex on a patent covering Upsher Smith’s Fortical®, a nasal formulation for osteoporosis.
  • UCB against KV, Mallinckrodt, Teva, and CorePharma on patent covering Metadate® CD, on ADHD medicine and Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to Keppra®, a leading epilepsy medicine.
  • Eli Lilly against Genentech in a patent litigation relating to monoclonal antibodies and against Teva Pharmaceuticals on patents involving Lilly's highly successful product Sarafem, which is used to treat Prementrual Dysphoric Disorder (PMDD), a severe form of PMS.
  • Emory against Glaxo Wellcome on patents relating to anti-hepatitis pharmaceuticals, and against Glaxo Wellcome and Bio Chem Pharma on patents relating to anti-AIDS pharmaceuticals.
  • Pfizer against Barr on patents relating to oral contraceptive pharmaceuticals, and against Barr on patents relating to hormone replacement therapy pharmaceuticals. 
  • Bristol-Myers Squibb against Housey Pharmaceuticals on patents relating to cell based assays and against Rhone-Poulenc Rorer, Inc. et. al. on patents relating to semi-synthetic process technology for making Taxol. 
  • Bausch & Lomb against Alcon and Allergan on patents relating to compositions for disinfecting contact lenses and against GNC, Leiner, Alcon, Rexall and Vitamin Health on a patent relating to a nutritional supplement to prevent macular degeneration.